Patents Assigned to Universitat Zurich
  • Patent number: 12383602
    Abstract: The invention relates to a HLA-B57 open conformer or a HLA-B57 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B57 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B57 Fc open conformer and immune checkpoint inhibitors and/or checkpoint agonist agents. Furthermore, the invention relates to the use of HLA-B57 open conformer as an immunomodulator, particularly in diseases where modulation of diverse immune cell components (e.g. cytotoxic CD8+ T cells, Tregs) is a therapeutic strategy, e.g. infectious diseases.
    Type: Grant
    Filed: June 26, 2022
    Date of Patent: August 12, 2025
    Assignees: UNIVERSITAT ZURICH, UNIVERSITAT BASEL
    Inventors: Osiris Marroquin Belaunzaran, Ulf Petrausch, Christoph Renner
  • Patent number: 12384839
    Abstract: Described herein is the use of a non-agonist ligand, particularly an antibody, specifically binding to GM-CSF or one of CD116, CD131 and the GM-CSF receptor composed of CD116 and CD131 for use in treatment of leukemia in a patient having undergone allo-HCT or in treatment of other complications arising as a consequence of hematopoietic cell transplantation from an immunologically non-identical donor.
    Type: Grant
    Filed: May 18, 2023
    Date of Patent: August 12, 2025
    Assignee: UNIVERSITAT ZURICH
    Inventors: Burkhard Becher, Sonia Tugues
  • Patent number: 12370221
    Abstract: The present invention concerns a method of generating a population of skeletal muscle derived human muscle precursor cells. For this purpose, a specialized FBS-free cell growth medium is used. The invention further concerns a composition comprising such a population of hMPCs for use as a medicament, especially in the treatment of skeletal muscle dysfunction.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: July 29, 2025
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Daniel Eberli, Deana Mohr, Souzan Salemi, Fahd Azzabi Zouraq
  • Publication number: 20250169889
    Abstract: A computer-implemented method, computing device, system and computer program product for assisting positioning of a tool (5) with respect to a specific body part (202) of a patient (200) comprising: receiving intraoperative imaging data (ID) comprising 2D images capturing the specific body part (202) from a plurality of perspectives and 2D image(s) capturing at least a part of the tool (5) from at least one perspective; reconstructing an anatomical 3D shape (AS) of the specific body part (202) using an artificial-intelligence based algorithm corresponding to the specific body part (202) based on the intraoperative imaging data (ID) and data indicative of perspectives of 2D images; estimating a current position (5c) of the tool (5) with respect to the anatomical 3D shape (AS) based on the intraoperative imaging data (ID); and generating positioning guidance data (GD) comprising the estimated current position (5c) of the
    Type: Application
    Filed: February 17, 2023
    Publication date: May 29, 2025
    Applicant: UNIVERSITÄT ZÜRICH, PROREKTORAT FORSCHUNG
    Inventors: Hooman ESFANDIARI, Philipp FÜRNSTAHL, Mazda FARSHAD
  • Publication number: 20250067741
    Abstract: The present invention relates to the field of assessment of the health status, particular with regard to prostate cancer risk, by measurement of certain proteins in human samples, in particular in human urine.
    Type: Application
    Filed: December 16, 2022
    Publication date: February 27, 2025
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Irina BANZOLA, Blaz PAVLOVIC, Nagjie Laila ALIJAJ, Daniel EBERLI
  • Patent number: 12227755
    Abstract: The invention relates to an infectious arenavirus particle that is engineered to contain a genome with the ability to amplify and express its genetic information in infected cells but unable to produce further infectious progeny particles in normal, not genetically engineered cells. One or more of the four arenavirus open reading frames glycoprotein (GP), nucleoprotein (NP), matrix protein Z and RNA-dependent RNA polymerase L are removed or mutated to prevent replication in normal cells but still allowing gene expression in arenavirus vector-infected cells, and foreign genes coding for an antigen or other protein of interest or nucleic acids modulating host gene expression are expressed under control of the arenavirus promoters, internal ribosome entry sites or under control of regulatory elements that can be read by the viral RNA-dependent RNA polymerase, cellular RNA polymerase I, RNA polymerase II or RNA polymerase III.
    Type: Grant
    Filed: June 22, 2022
    Date of Patent: February 18, 2025
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Daniel D. Pinschewer, Lukas Flatz, Andreas Bergthaler, Rolf Zinkernagel
  • Patent number: 12225900
    Abstract: A perfusion loop assembly for ex vivo liver perfusion includes a pump providing perfusion fluid through a line branching at a branching point into a first branch line and a second branch line. The first branch line provides a first portion of the perfusion fluid to the hepatic artery of the liver, the first branch line coupled with a gas exchanger, where the first branch line includes a flow rate sensor and/or a pressure sensor. The second branch line provides a second portion of the perfusion fluid to the portal vein of the liver; the second branch line includes a valve for controlling flow of perfusion fluid into the portal vein. The second branch line includes a flow rate sensor and/or a pressure sensor. A liver chamber assembly holds the liver ex vivo, and an outlet line for the perfusion fluid connects the liver chamber assembly and the pump.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: February 18, 2025
    Assignees: ETH Zurich, Universität Zurich
    Inventors: Dustin Becker, Dilmurodjon Eshmuminov, Max Leo Hefti, Martin Jörg Schuler, Philipp Rudolf von Rohr, Pierre-Alain Clavien, Rolf Graf, Lucia Bautista Borrego, Xavier Muller, Philipp Dutkowski
  • Patent number: 12226475
    Abstract: The present invention relates to compositions, immunogenic or vaccine compositions and pharmaceutical compositions for the prevention or treatment of insect bite 5 hypersensitivity of equine mammals, preferably of horses. Furthermore, the invention provides methods for preventing or treating insect bite hypersensitivity of equine mammals, preferably of horses.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: February 18, 2025
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Antonia Fettelschoss, Martin Bachmann
  • Patent number: 12195717
    Abstract: The present invention relates to a cell culture device (1) for use with an optical microscope (40), comprising a housing (10) that is configured to be placed onto a stage of an optical microscope (40) in front of an objective (41) of the microscope (40), the housing (10) enclosing an internal space (11) of the housing (10), a removable flow chamber (2) enclosing an internal space (20) for accommodating a cell culture (CC) comprising living biological cells, a heater (3) arranged in the internal space (11) of the housing (10) for heating said fluid medium (M) to be guided through the flow chamber (2), a first flow path (P1) arranged in the internal space (11) of the housing (10) for guiding said fluid medium (M) towards the flow chamber (2) via said heater (3), and a second flow path (P2) arranged in the internal space (11) of the housing (2) for guiding said fluid medium (M) away from the flow chamber (2), and a pump (4) for pumping said fluid medium (M) through the first flow path (P1) into the internal spac
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: January 14, 2025
    Assignees: UNIVERSITÄT ZÜRICH, NTNU-NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET
    Inventors: Carlo Kriesi, Vartan Kurtcuoglu, Anastasios Marmaras, Martin Steinert
  • Patent number: 12175358
    Abstract: The present disclosure relates to a routing circuit for routing signals between neuron circuits of an artificial neural network, the routing circuit comprising: a first memory cell (302) having an input coupled to a first input line (304) of the routing circuit and an output coupled to a first column line (308); a second memory cell (302) having an input coupled to a second input line (304) of the routing circuit and an output coupled to the first column line (308); and a first comparator circuit (310) configured to compare a signal (IREAD1) on the first column line (308) with a reference level, and to selectively assert a signal (VOUT1) on a first output line (312) of the routing circuit based on the comparison.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: December 24, 2024
    Assignees: COMMISSARIAT À L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, UNIVERSITÄT ZÜRICH
    Inventors: Thomas Dalgaty, Giacomo Indiveri, Melika Payvand, Elisas Vianello
  • Patent number: 12163626
    Abstract: A cryostat for operation with liquid helium, may comprise a primary chamber with a main region and a pot region for containing a bath of liquid helium-4, primary inlet means for introducing liquid helium-4 and primary outlet means for releasing gaseous helium-4, the primary inlet means comprising a transfer line extending into the primary region. The cryostat may be configured for operation under a continuous supply of liquid helium-4 and at a reduced helium-4 pressure, whereby gaseous helium-4 is pumped off through the outlet means. The primary chamber may comprise a baffle structure arranged between the pot region and the main region, the baffle structure defining at least one flowpath for the flow of gaseous helium-4, each flowpath forming a detoured connection between the pot region and the main region.
    Type: Grant
    Filed: February 7, 2020
    Date of Patent: December 10, 2024
    Assignee: UNIVERSITAT ZURICH
    Inventors: Dominik Biscette, Johan Chang, Denys Sutter
  • Publication number: 20240368266
    Abstract: The present invention relates to antibodies binding to human interleukin-2 (hIL-2). The invention more specifically relates to humanized antibodies specifically binding a particular epitope of hIL-2 and, when bound to this epitope, displaying a unique capability of inhibiting binding of hIL-2 to CD25.
    Type: Application
    Filed: November 14, 2023
    Publication date: November 7, 2024
    Applicant: Universität Zürich
    Inventors: Natalia Arenas-Ramirez, Iwan Beuvink, Onur Boyman, Barbara Brannetti, Andreas Katopodis, Simone Popp, Catherine Regnier, Chao Zou
  • Patent number: 12109404
    Abstract: The invention relates to a radial blood pump (1) for supporting a blood flow (106) in a human or animal heart (205) comprising a first and a second inlet channel (41, 42), a first outlet channel (51, 52), a first electric motor (71) comprising a first stator (77) and a first internal rotor (75), wherein the first electric motor (71) is configured to drive an impeller (2, 2a, 2b) arranged at an intersection of the first with the second inlet channel (41, 42), wherein the impeller (2, 2a, 2b) is connected to the first internal rotor (75) and wherein the impeller (2, 2a, 2b) comprises a merging portion (22) arranged at the intersection, where a merging of a first blood flow (106) coming from the first inlet channel (41) and a second blood flow (107) coming from the second inlet channel (42) takes place, wherein the impeller (2, 2a, 2b) is configured to pump the first and second blood flow (106, 107) from the first and second inlet channel (41, 42) via the merging portion (22) to the first outlet channel (51), a
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: October 8, 2024
    Assignee: UNIVERSITÄT ZÜRICH
    Inventors: Marcus Granegger, Michael Hübler, Bente Thamsen, Martin Schweiger
  • Publication number: 20240329043
    Abstract: The disclosure relates to the field of multiple sclerosis (MS) stratification by analyzing the body fluid of an MS patient. The invention also relates to the field of antigen specific immunotherapies, such as the induction of tolerance.
    Type: Application
    Filed: July 14, 2022
    Publication date: October 3, 2024
    Applicant: Universität Zurich
    Inventors: Mireia SOSPEDRA RAMOS, Roland MARTIN, Raquel PLANAS, Andreas LUTTEROTTI
  • Publication number: 20240310378
    Abstract: The invention provides a method of predicting the prognosis of a breast cancer patient by determining the expression level of p53 and GATA in a lymph node metastasis sample. The invention further encompasses pharmaceutical compositions, or methods of treating patients with a good or poor prognosis identified using the above methods, in addition to a kit, or system comprising the means to determine an expression level of p53 and/or GATA3 in a lymph node metastasis sample.
    Type: Application
    Filed: February 11, 2022
    Publication date: September 19, 2024
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Jana FISCHER, Hartland JACKSON, Bernd BODENMILLER
  • Patent number: 12054708
    Abstract: The invention relates to a method for identifying and quantifying a polypeptide from a library of polypeptides. The method comprises the steps of: 1—providing a polypeptide library and a detection tag library, 2—generating a nested library comprising the polypeptides and the detection tags, 3—sequencing the nested library, 4—selecting a member of the nested library in one or several selection steps that are independent of a physical genotype-phenotype linkage, 5—isolating the detection tag from the selected polypeptide, 6—identifying and quantifying the detection tag by mass spectrometry, 7—obtaining the sequence of the selected polypeptide. The invention also relates to a collection of polypeptides, a collection of detection tags, and a collection of plasmid vectors.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: August 6, 2024
    Assignee: Universität Zürich
    Inventors: Markus Seeger, Pascal Egloff, Iwan Zimmermann
  • Publication number: 20240237987
    Abstract: An occlusion device is provided for occluding a left atrial appendage (LAA), including a compliant balloon defining a fluid-tight balloon chamber, and an actuating shaft, which is disposed at least partially within the balloon chamber for setting a distance between distal and proximal end portions of the balloon. A proximal LAA-orifice cover includes a frame and a covering fixed to the frame. An orifice-support stent is fixed to and extends distally from the proximal LAA-orifice cover, and is generally cylindrical when in a radially-expanded state. Other embodiments are also described.
    Type: Application
    Filed: March 28, 2024
    Publication date: July 18, 2024
    Applicant: UNIVERSITÄT ZÜRICH Zurich
    Inventors: Andrea GUIDOTTI, Francesco MAISANO, Monica TOCCHI, Boaz HARARI, Georgios STEFOPOULOS, Pietro GOZZOLI, Luca VICENTINI
  • Publication number: 20240238377
    Abstract: The invention relates to a combination medicament for treatment of malignant neoplastic disease. The combination medicament comprises an IL-12 polypeptide having a biological activity of IL-12 or a nucleic acid expression vector comprising a sequence encoding such IL-12 polypeptide, and a non-agonist blockade of T-cell inhibitory molecules, including non-agonist LAG-3 ligand, non-agonist TIM-3 ligand, non-agonist BLTA ligand, non-agonist TIGIT ligand, non-agonist VISTA ligand, non-agonist B7/H3 ligand, non-agonist CTLA-4 ligand or non-agonist PD-1 ligand, particularly an anti-CTLA-4 or anti-PD-1 immunoglobulin G.
    Type: Application
    Filed: April 8, 2024
    Publication date: July 18, 2024
    Applicant: UNIVERSITAT ZURICH
    Inventors: Burkhard BECHER, Johannes VOM BERG
  • Publication number: 20240228555
    Abstract: The present invention is directed to peptidomimetics having antibacterial activity, especially against Gram-negative bacteria. The peptidomimetics of the invention are compounds of the general formula (I), P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-P15-P16 (I) and pharmaceutically acceptable salts thereof, as described in the description and in the claims. The invention is also directed to therapeutic uses of the peptidomimetics for the treatment or prevention of bacterial infections and diseases related to bacterial infections and to non-therapeutic uses of the peptidomimetics for preserving or disinfecting foodstuffs, cosmetics, medicaments or other nutrient-containing materials. In addition, the present invention provides an efficient synthetic process by which these compounds can, if desired, be made in parallel library-format. Moreover, the peptidomimetics of the invention show improved antimicrobial activity, low or no hemolysis of red blood cells and reduced cytotoxicity.
    Type: Application
    Filed: August 5, 2021
    Publication date: July 11, 2024
    Applicants: Basilea Pharmaceutica International AG, Allschwil, UNIVERSITÄT ZÜRICH
    Inventors: Daniel OBRECHT, Anatol LUTHER, Grégory UPERT, Nicolas DESJONQUERES, Emile BRABET, Peter ZBINDEN, Oliver ZERBE, Kerstin MÖHLE
  • Publication number: 20240225518
    Abstract: The present invention relates to a medical system (20) for measuring visual evoked potentials (VEP) of a person, comprising a display (2) for displaying images to be observed by the person with a single eye, and an image generating module (1), the image generating module (1) being configured to cause the display (2) to display a sequence of images comprising a first image and a second image. The medical system (20) further comprises: a plurality of electrodes (3) configured to be attached to the scalp of the person and to detect EEG signals indicative of electrical activity in the brain of the person in response to observing said sequence of images displayed by the display (2), an EEG recording module (4) connected to said plurality of electrodes (3), the EEG recording module (4) being configured to record said EEG signals, and an analyzing module (8), the analyzing module (8) being configured to derive from said EEG signals recorded by the EEG recording module (4) at least one visual evoked potential (VEP).
    Type: Application
    Filed: May 3, 2023
    Publication date: July 11, 2024
    Applicant: UNIVERSITÄT ZÜRICH
    Inventors: Valentine MARCAR, Marcus CHEETHAM